Consolidated Financial Results for the Nine Months Ended October 31, 2025 [Japanese GAAP]12/15TDnetPDF(296KB)
SanBio Obtains Partial Change Approval for“AKUUGO(R) Suspension for Intracranial Implantation” 12/9TDnetPDF(251KB)
Announcement of Determination of Issue Price and Other Matters for Issuance of New Shares Through an International Offering11/6TDnetPDF(127KB)
Notice Regarding the Subcommittee Review Results on Partial Change Approval for AKUUGO(R)10/16TDnetPDF(447KB)
Notice Regarding Inclusion of AKUUGO(R) Suspension for intracranial Implantation on the Committee Agenda10/2TDnetPDF(221KB)
Presentation for Financial Results for the 2nd Quarter of the Fiscal Year Ending January 31, 20269/18TDnetPDF(1MB)
Revision of Consolidated Earnings Forecast for the Fiscal Year Ending January 20269/12TDnetPDF(175KB)
Consolidated Financial Results for the Six Months Ended July 31, 2025 [Japanese GAAP]9/12TDnetPDF(470KB)
Notice Regarding Revision of Expected Approval Timing for Partial Changes to AKUUGO(R)Suspension for Intracranial Implantation6/25TDnetPDF(166KB)
Consolidated Financial Results for the Three Months Ended April 30, 2025 [Japanese GAAP]6/13TDnetPDF(391KB)